ADC Therapeutics SA (ADCT)

NYQ – Цена в реальном времени. Валюта: USD

3.43

-0.05 (-1.44%)

При закрытии: May 12, 2026, 4:00 PM EDT

3.45

+0.02 (0.58%)

До открытия: May 13, 2026, 5:17 AM EDT

05.05.2026

ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL

ADC Therapeutics SA remains a Strong Buy, driven by pivotal ZYNLONTA combination trials targeting 2nd-line r/r DLBCL. Topline data from the phase 3 LOTIS-5 trial (ZYNLONTA + rituximab) is expected in Q2 2026, representing a major inflection point. ZYNLONTA + glofitamab in phase 1b LOTIS-7 achieved an 89.8% ORR and 77.6% CR rate, with further data expected by the end of 2026.

04.05.2026

ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript

04.05.2026

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.36 per share a year ago.

04.05.2026

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2026, and provided recent operational updates.

01.05.2026

Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?

Here is how ADC Therapeutics SA (ADCT) and Bioventus (BVS) have performed compared to their sector so far this year.

01.05.2026

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 49,400 of the Company's common shares to two new employees on May 1, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

27.04.2026

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to report financial results for the first quarter of 2026 and provide operational updates.

Видео

No Data

There is no data to display

Пресс-релизы

04.05.2026

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

01.05.2026

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

01.04.2026

ADC Therapeutics Announces New Employee Inducement Grant

LAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on April 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.

10.03.2026

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026 Recent amendment to HealthCare Royalty financing agreement increases strategic flexibility Fourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent operational updates.

ADC Therapeutics SA (ADCT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

ADC Therapeutics SA (ADCT)

ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL

ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

Видео

No Data

Пресс-релизы

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL

ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

Видео

No Data

Пресс-релизы

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Search stocks

ADC Therapeutics SA (ADCT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

ADC Therapeutics SA (ADCT)

ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL

ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

Видео

No Data

Пресс-релизы

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL

ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

Видео

No Data

Пресс-релизы

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update